Carteyva (relmacabtagene autoleucel or relma-cel injection) is an autologous anti-CD19 CAR-T cell immunotherapy approved in China for three types of lymphoma. This advanced CAR T cell therapy is developed based on the CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company), featuring with long-term remission and milder side effects.
In addition to hematologic malignancies, Carteyva also presents promising outcomes in systemic lupus erythematosus (SLE) in clinical studies.
Carteyva is a prescription medicine used to treat three types of non-Hodgkin lymphoma in adults with:
Carteyva brings together global-level design with local innovation, making advanced CAR-T therapy more practical for real-world clinical use.
Patient Voices: Their Stories, In Their Words
China has emerged as a global leader in CAR-T cell therapy research and innovation, with rapid advancements in both clinical application and technology development. From state-of-the-art manufacturing platforms to breakthroughs in next-generation CAR designs, Chinese research institutions and biotech companies are driving the evolution of CAR-T therapy for blood cancers and beyond. Supported by strong government policy, large-scale clinical trial networks, and world-class expertise, China’s CAR-T programs offer cutting-edge solutions with faster development timelines and increasingly accessible treatment options. This technology excellence positions China at the forefront of personalized cancer immunotherapy worldwide.
CAR T Cells China associated cancer care experts specialize in the diagnosis and treatment of blood cancers, including leukemia, lymphoma, and multiple myeloma, across all stages — from early to advanced, as well as rare and complex cases. Our hematology-oncology team integrates standard treatments with the latest innovations, including CAR-T cell therapy, a cutting-edge form of immunotherapy that reprograms the patient’s own immune cells to fight cancer. We also offer precision medicine approaches and targeted therapies, ensuring each patient receives care tailored to their specific cancer profile. Qualified patients may also gain access to clinical trials and investigational CAR-T therapies, giving them the opportunity to benefit from the most advanced treatment options available today.
Cancer is a complex disease that involves multiple appointments, specialized treatments, medications, and ongoing follow-up care — all of which can feel overwhelming, especially for international patients. At CAR T Cell China, we understand these challenges and are committed to supporting you every step of the way. That’s why we’ve developed a dedicated international patient care model, where a personal care coordinator or team is assigned to help manage the entire treatment journey — from visa support and travel logistics to hospital navigation and medical appointments.
Your care manager at CAR T Cell China is a highly trained nurse or patient liaison with deep expertise in cancer care and CAR-T therapy. They serve as your primary point of contact, coordinating everything from consultations with top specialists to treatment scheduling, medication support, and ongoing communication with your medical team.
As a trusted bridge between you and your care providers, your care manager ensures that no detail is overlooked — allowing you to focus fully on your recovery, while we handle the rest.
Finding the right cancer treatment center and care team is one of the most important decisions you’ll make — especially when seeking care abroad. At CAR T Cell China, we understand the weight of that decision and the stress it can bring. That’s why we are committed to making your experience as convenient, affordable, and worry-free as possible. From personalized care coordination to access to cutting-edge CAR-T therapy, we work every day to ensure that international patients receive not only world-class treatment, but also the dedicated support they need throughout their journey. Here are just a few of the key advantages of choosing CAR T Cell China as your care destination.
A cancer diagnosis affects every part of your life—your body, health, emotions, relationships, and future plans. At CAR T Cells China, we understand that each patient’s experience is unique. That’s why our expert team takes the time to understand your specific needs, diagnosis, and personal goals to create a treatment plan centered around you.
Our difference lies in delivering advanced, personalized care through cutting-edge CAR-T cell therapy. Backed by leading cancer specialists and the latest in immunotherapy innovation, we work collaboratively to provide comprehensive support—guiding you through every step of the CAR-T treatment journey with compassion, precision, and care.
China has experienced remarkable growth in the field of medicine over the past few decades, reflecting its broader advancements in science and technology. The country has made substantial investments in healthcare infrastructure, research, and development, which have significantly improved its medical capabilities. Cutting-edge facilities, increased funding for biomedical research, and a focus on innovation have enabled China to make strides in various areas of medicine, including CAR T-cell therapy.
CAR T-cell therapy has seen substantial progress in China, with several therapies approved for treating blood cancers like lymphoma, acute lymphoblastic leukemia and multiple myeloma. The NMPA has streamlined approval processes, and domestic companies are actively developing new therapies and reducing costs. Research and clinical trials are vibrant, focusing on improving efficacy and managing side effects. China is making significant strides in expanding the availability and innovation of CAR T-cell therapies.
China has made significant strides in medical care and research, including advancements in CAR T-cell therapy.
China’s rapid advancements in biotechnologies are establishing it as a leader in CAR T-cell therapy, ensuring effective treatments.
China offers effective CAR T-cell therapies and other medical services with patient-friendly pricing and an accessible approach.
Timely treatment enhances recovery, reduces complications, and improves healthcare efficiency and patient satisfaction.
In China, Carteyva is only provided at certified treatment centers, these centers/hospitals usually are leading hospitals in the region, where the medical staff are highly skilled in managing lymphoma, and are specially trained to take care of you during the entire CAR T-cell therapy process.
You should plan to stay at the certified treatment center for at least one week following the infusion, and you’ll have several appointments before and after the treatment. Your treatment team will advise you on how close you need to be to a certified healthcare facility during the first four weeks after the infusion.
